R. Ebert

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Michael A. Nauck, Markus M. Heimesaat, Jens J. Holst et al. · Journal of Clinical Investigation · 1993 · 1.6K citations · Full text

Glycobiology, Preserved Incretin Activity, Plasma Gip +18

Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

Michael A. Nauck, F. Stöckmann, R. Ebert et al. · Diabetologia · 1986 · 1.3K citations · Full text

Obesity, Medicine, Insulin Management +6

Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*

Michael A. Nauck, ERWIN HOMBERGER, E. G. Siegel et al. · The Journal of Clinical Endocrinology & Metabolism · 1986 · 866 citations

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

Michael A. Nauck, Eckart Bartels, R. Ebert et al. · The Journal of Clinical Endocrinology & Metabolism · 1993 · 475 citations

G Oral Glucose, Glucagon-like Peptide-1-, Insulin Signaling +16

Adenosine release from isolated fat cells and its significance for the effects of hormones on cyclic 3?,5?-AMP levels and lipolysis

Ulrich Schwabe, R. Ebert, H. C. Erbler · Naunyn-Schmiedeberg s Archives of Pharmacology · 1973 · 210 citations

Metabolic Syndrome, Health Sciences, Biochemistry +12